NCT05662098Active, not recruitingEarly phase 1
Alternative Dosing And Prevention of Transfusions (ADAPT)
Alternative Dosing And Prevention of Transfusions (ADAPT): A Prospective Study to Reduce Transfusion Requirements for Children With Sickle Cell Anemia Using Pharmacokinetics-based Hydroxyurea Dosing
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
ADAPT is a prospective cohort study at Jinja Regional Referral Hospital (JRRH) primarily to assess the effect of hydroxyurea on blood transfusion utilization and secondarily to determine the feasibility of PK-guided hydroxyurea dosing.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 4 Oct 2022
- Start date
- 16 Jun 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Diseases
- Sickle cell disease
- NCT number
- NCT05662098
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 100
- From 16 Jun 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known malignancy or other known chronic illnesses including but not limited to active tuberculosis, renal disease
- Current participation in other therapeutic clinical trials, or within 6 months of prior disease-modifying treatments
Other
- Current hydroxyurea treatment (or within the past 6 months)
- Regular blood transfusions (6 or more within the past 12 months)
- Transfusion within the last 30 days (temporary exclusion)
Who the study is looking for
- Patients with documented HbSS disease
- Age: ≥ 12 months and ≤ 10 years of age, at the time of enrollment
- Parent or guardian willing and able to provide informed consent
- Able to comply with all study related treatments, evaluations, and follow-up
Age in the registry: 12 months to 10 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jinja Regional Referral Hospital (JRRH), Department of Paediatrics, Sickle Cell Clinic Coordinator of this site? Confirm its status | Jinja | Uganda | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.